肝硬度测量在原发性硬化性胆管炎中的预后价值:前瞻性FICUS队列
FICUS前瞻性队列纳入538例无并发症PSC患者,每年记录临床、生化和FibroScan肝硬度测量(LSM)数据,中位随访60.7个月。基线LSM独立预测无移植生存,LSM进展者死亡或移植风险显著升高(aHR 3.12),支持LSM用于风险分层和作为试验替代终点。
要点
- 基线LSM与PSC无移植生存独立相关,≥15 kPa组5年无移植生存仅46.0%
- LSM每年每增加1 kPa,死亡或移植风险增加18%
核心结论
- 前瞻性FICUS队列验证了FibroScan所测静态和动态LSM在PSC中具有强预后价值。
- LSM可作为PSC风险分层工具和临床试验的潜在替代终点。
研究设计与样本
- 前瞻性队列研究,每年记录成人无并发症PSC患者的临床、生物和LSM数据,持续5年。
- 共分析538例至少有1次可靠LSM且有随访数据的患者,中位随访60.7个月(IQR 48.6-66.0个月)。
- LSM按连续变量或Baveno VII的3个分类(<10 kPa、≥10至<15 kPa、≥15 kPa)评估,主要终点为无移植生存。
- 采用时间依赖多变量Cox回归分析校正风险比和95%CI,用联合模型评估LSM变化效应。
- 进展定义为个体LSM斜率显著为正。
主要发现
- 基线LSM与死亡或移植风险强烈且独立相关。
- 2.5至<10 kPa、10至<15 kPa、≥15 kPa组的5年无移植生存分别为93.9%(IQR 90.3%-96.2%)、78.1%(IQR 66.2%-86.3%)、46.0%(IQR 34.6%-56.7%)。
- LSM每年每增加1 kPa,死亡或移植风险增加18%。
关键数值与推荐
- LSM分类采用Baveno VII标准:<10 kPa、≥10至<15 kPa、≥15 kPa。
- 基线LSM ≥15 kPa组5年无移植生存46.0%(IQR 34.6%-56.7%)。
- LSM每年每增加1 kPa与死亡或移植风险增加18%相关。
临床怎么用
- 可将FibroScan LSM用于PSC患者的风险分层,基线LSM较高者需更密切监测。
- 动态监测LSM变化有助于识别疾病进展风险更高的患者。
- LSM可作为临床试验中评估治疗效果的潜在替代终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Predicting outcomes of primary sclerosing cholangitis (PSC) by reliable and simple tools is an unmet need. Retrospective studies have suggested that liver stiffness measurement (LSM) by vibration-controlled transient elastography (FibroScan, Echosens) can predict outcomes. We aimed to validate the prognostic value of LSM statics and determine the relevance of LSM dynamics in a large, prospective, cohort study. METHODS: Clinical, biological, and LSM data of adult patients with uncomplicated PSC were prospectively recorded annually for 5 years. LSM was assessed continuously or according to 3 Baveno VII classes (<10 kPa, ≥10 to <15 kPa, and ≥15 kPa). The primary end point was transplant-free survival. Adjusted hazard ratios and 95% confidence intervals were determined using time-dependent multivariable Cox regression analyses. Effect of LSM change was evaluated using joint modeling. Progression was defined by a significantly positive individual LSM slope. RESULTS: The study analyzed 538 patients with at least 1 reliable LSM and follow-up available (median, 60.7 months; interquartile range [IQR], 48.6-66.0 months). Median baseline LSM was 7.6 kPa (IQR, 5.8-11.7 kPa). Nineteen patients died, and 72 received a transplant. Baseline LSM was strongly and independently linked to the risk of death or transplantation. For the groups 2.5 to <10 kPa, 10 to <15 kPa, and ≥15 kPa, the 5-year transplant-free survival was 93.9% (IQR, 90.3%-96.2%), 78.1% (IQR, 66.2%-86.3%), and 46.0% (IQR, 34.6%-56.7%), respectively. Progressors experienced worse transplant-free survival vs nonprogressors: adjusted hazard ratio of 3.12 (95% confidence interval, 1.55-6.24; P = .001). Each 1-kPa/y increment was associated with 18% increase in risk of death or transplantation. CONCLUSIONS: This observational study validates the strong prognostic value of both static and dynamic LSM in PSC, as assessed by FibroScan. These results support the use of LSM as a risk stratification tool and potential surrogate end point in clinical trials.
引用
- Chazouilleres O, Bellet J, Schramm C, et al. Prognostic Performance of Liver Stiffness Measurements in Primary Sclerosing Cholangitis: The Prospective FICUS cohort. Gastroenterology. 2026. PMID: 42551570. doi:10.1053/j.gastro.2026.07.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。